Current Evidence on IL-17 and IL-(12)/23 Inhibitor Safety during Pregnancy in Psoriasis: A Call for Harmonized Data Collection
Liana Barenbrug, Julia van Praag, Marleen M.H.J. van Gelder, Renate G. van der Molen, Elke M.G.J. de Jong, Juul M.P.A. van den Reek · 2026
Read Current Evidence on IL-17 and IL-(12)/23 Inhibitor Safety during Pregnancy in Psoriasis: A Call for Harmonized Data Collection by Liana Barenbrug, Julia van Praag, Marleen M.H.J. van Gelder, Renate G. van der Molen, Elke M.G.J. de Jong, Juul M.P.A. van den Reek (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13551568.txt.
Description
Liana Barenbrug and co-authors review what is known about newer psoriasis drugs in pregnancy in a 2026 paper. The drugs block interleukin-17 or the interleukin-12 and 23 paths, but proof on safety before and during pregnancy is thin.
High disease activity in pregnancy also harms outcomes, so doctors face a hard trade-off. The team ran a full search of past studies for mother, father, and baby outcomes by drug class. Gaps are wide, and data are logged in mixed ways. The authors call for one shared way to collect facts. Clinicians get a clear view of what is known and what is still missing.
Catalog record
| CREATOR | Liana Barenbrug, Julia van Praag, Marleen M.H.J. van Gelder, Renate G. van der Molen, Elke M.G.J. de Jong, Juul M.P.A. van den Reek |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |